Besides different treatment regimens for rGBM, no prognostic factor (including age, sex, KPS, recurrent tumor volume, IDH1 mutation status, and MGMT promotor methylation status) has been reported to exert a significant impact on OS and PFS (60). This evidence concerns the gene IDH1 and neoplasm.